Literature DB >> 24421531

Drug monographs: pomalidomide and ponatinib.

Taylor W Butler, J Aubrey Waddell, Dominic A Solimando1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2013        PMID： 24421531      PMCID： PMC3847975          DOI： 10.1310/hpj4808-636

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  7 in total

1.  A phase-2 trial of low-dose pomalidomide in myelofibrosis.

Authors:  K H Begna; R A Mesa; A Pardanani; W J Hogan; M R Litzow; R F McClure; A Tefferi
Journal:  Leukemia       Date:  2010-11-05       Impact factor: 11.528

2.  Phase I trial of pomalidomide given for patients with advanced solid tumors.

Authors:  Matthew M Cooney; Charles Nock; Joseph Bokar; Smitha Krishnamurthi; Joseph Gibbons; Mary Beth Rodal; Anne Ness; Scot C Remick; Robert Dreicer; Afshin Dowlati
Journal:  Cancer Chemother Pharmacol       Date:  2012-08-09       Impact factor: 3.333

3.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

Authors:  S A Schey; P Fields; J B Bartlett; I A Clarke; G Ashan; R D Knight; M Streetly; A G Dalgleish
Journal:  J Clin Oncol       Date:  2004-07-12       Impact factor: 44.544

4.  Pomalidomide is active in the treatment of anemia associated with myelofibrosis.

Authors:  Ayalew Tefferi; Srdan Verstovsek; Giovanni Barosi; Francesco Passamonti; Gail J Roboz; Heinz Gisslinger; Ronald L Paquette; Francisco Cervantes; Candido E Rivera; H Joachim Deeg; Juergen Thiele; Hans M Kvasnicka; James W Vardiman; Yanming Zhang; B Nebiyou Bekele; Ruben A Mesa; Robert P Gale; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

5.  Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.

Authors:  Matthew J Streetly; Kylie Gyertson; Yvonne Daniel; Jerome B Zeldis; Majid Kazmi; Stephen A Schey
Journal:  Br J Haematol       Date:  2008-04       Impact factor: 6.998

6.  Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Authors:  Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

7.  Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.

Authors:  Matthew Hoffmann; Claudia Kasserra; Josephine Reyes; Peter Schafer; Jolanta Kosek; Lori Capone; Anastasia Parton; Heasook Kim-Kang; Sekhar Surapaneni; Gondi Kumar
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-01       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.